[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University of Missouri-Columbia\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":596},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,60,0,25,[9,49,74,100,129,161,179,201,223,242,263,280,307,329,360,382,399,416,436,462,482,512,530,551,578],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100625549","metacognitive-strategy-training-intervention-for-transition-age-youth-with-cerebral-palsy-100625549",false,"NCT07424079","Metacognitive Strategy Training Intervention for Transition-Age Youth With Cerebral Palsy","The Feasibility of Remote Pathways and Resources for Engagement and Participation (PREP) for Transition-Age Youth With Cerebral Palsy and Primary Caregivers","Inclusion Criteria:\n\n* Youth aged 13 -17 with CP and one primary parent, guardian, or caregiver aged 18 or older\n* Youth ability to self-mobilize with or without adaptive equipment measured by the Gross Motor Function Scale-Expanded \\& Revised (GMFCS-E\\&R) Levels I - III\n* Effective youth communication measured by Communication Function Classification System (CFCS) Levels I - III\n* Ability to read, speak, and write English\n* Willingness to participate in all aspects of the proposed study.\n\nExclusion Criteria:\n\n* Youth with profound intellectual disability\n* Youth with severe mental health conditions\n* Youth who engage in community-based transition services redundant with remote PREP","ALL","13 Years","17 Years",{"count":21,"type":22},24,"ESTIMATED","INTERVENTIONAL",[25],"NA","This exploratory randomized controlled trial will examine the feasibility and preliminary effects of a remote PREP intervention compared to an attention control for transition-age youth with cerebral palsy and their caregivers. Youth-caregiver dyads will complete remote baseline assessments and be randomized to a 12-week intervention or attention control, with weekly virtual sessions. Feasibility outcomes will be primary, with secondary outcomes exploring preliminary efficacy. Post-intervention assessments and optional interviews will be conducted remotely to capture outcomes and participant experiences.",[28],"Cerebral Palsy (CP)",[30,31,32,33,34,35],"Cerebral Palsy","Occupational Therapy","Adolescents","Caregivers","Transition Planning","Participation","NOT_YET_RECRUITING","2026-08-17",{"date":39,"type":40},"2026-08-19","ACTUAL",{"date":42,"type":22},"2026-08-31",{"date":44,"type":22},"2027-02-28",{"name":46,"class":47},"University of Missouri-Columbia","OTHER",1,{"id":50,"slug":51,"hasResults":12,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":12,"sex":17,"minAge":56,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":23,"phases":59,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":48},"100581086","absorbable-vs-non-absorbable-sutures-for-hip-capsular-closure-100581086","NCT06845735","Absorbable vs Non-Absorbable Sutures for Hip Capsular Closure","Prospective Randomized Control Trial Comparing Absorbable Sutures to Non-Absorbable Sutures for Capsular Closures in Hip Arthroscopies","Inclusion Criteria:\n\n* Subjects 18 years of age and older.\n* Subject requiring surgical hip arthroscopic intervention for their hip pathology\n\nExclusion Criteria:\n\n* Subjects less than 18 years of age.\n* Subjects with any other medical problem precluding anesthesia or surgery.\n* Unable to provide informed consent.","18 Years",{"count":58,"type":22},100,[25],"The study is to prospectively compare absorbable sutures with non-absorbable sutures used for capsular repair during hip arthroscopic procedures. Major outcomes will be measured using three questionnaires ((1) International Hip Outcome Tool-12 (iHOT-12), (2) modified Harris hip score, (3) hip outcome score) in addition to the standard of care set of 9 questionnaires. The other major outcome will be any radiographic heterotrophic ossification at the 6-month follow-up time point.",[62,63,64],"Labrum Injury of the Hip Joint","Hip Arthroscopy","Femoroacetabular Impingement Syndrome","RECRUITING","2026-08-06",{"date":68,"type":40},"2026-08-10",{"date":70,"type":40},"2024-03-22",{"date":72,"type":22},"2028-01-01",{"name":46,"class":47},{"id":75,"slug":76,"hasResults":12,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":82,"sex":17,"minAge":56,"maxAge":83,"enrollmentInfo":84,"targetDuration":4,"studyType":86,"phases":4,"briefSummary":87,"conditions":88,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":48},"100639487","growth-hormone-resistance-of-beta-cells-100639487","NCT07581860","Growth Hormone Resistance of Beta-cells","Growth Hormone Resistance of Beta-cells in People With Impaired Fasting Glucose vs Impaired Glucose Tolerance","GHRB-C","Inclusion Criteria:\n\n* body mass index \\>18.5kg\u002Fm2 and \\\u003C45.9kg\u002Fm2\n* impaired fasting glucose \\>\u002F= 100mg\u002FdL, \\\u003C\u002F= 126mg\u002FdL or impaired glucose tolerance on 75g oral glucose tolerance test (blood glucose 140 to 199mg\u002FdL at two-hours)\n\nExclusion Criteria:\n\n* pregnant, planning to become pregnant during the study, or breastfeeding\n* current diagnosis or history of type 1 or type 2 diabetes\n* use of medications that can impact the study outcomes (e.g., GLP-1 receptor agonists)\n* history of bariatric surgery\n* known, uncontrolled hypothyroidism\n* history of intracranial hypertension, including papilledema, or a condition that increases the risk of developing intracranial hypertension, such as Turner Syndrome, Prader-Willi Syndrome, or renal impairment\n* current cancer or cancer that has been in remission less than 5 years\n* first degree relative with type 1 diabetes\n* evidence of anemia or significant end organ dysfunction (e.g., liver, kidney, heart disease)\n* alcohol use disorder, use of controlled substances, or smoking \\>2 cigarettes per day\n* greater than 3% weight loss within three months of screening or engaged in regular (\\>\u002F= 3 days per week), continuous moderate- or high-intensity exercise of \\>\u002F= 30 min duration\n* mentally disabled persons, prisoners, and persons with inability to grant voluntary informed consent",true,"59 Years",{"count":85,"type":22},10,"OBSERVATIONAL","The purpose of the research study is to better understand how beta-cells (cells in the pancreas that make insulin and help regulate blood sugar) respond to growth hormone in people with impaired fasting glucose or impaired glucose tolerance at the University of Missouri. The aim of the study is to advance understanding of how growth hormone affects beta-cells and risk factors for developing type 2 diabetes.",[89,90,91,92],"Healthy","Obesity & Overweight","Impaired Fasting Glucose (IFG)","Impaired Glucose Tolerance (Prediabetes)","2026-08-03",{"date":66,"type":40},{"date":96,"type":22},"2026-08-01",{"date":98,"type":22},"2030-09-01",{"name":46,"class":47},{"id":101,"slug":102,"hasResults":12,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":4,"eligibilityCriteria":106,"healthyVolunteers":12,"sex":17,"minAge":56,"maxAge":107,"enrollmentInfo":108,"targetDuration":4,"studyType":23,"phases":110,"briefSummary":111,"conditions":112,"keywords":114,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":48},"100610738","effects-of-grape-consumption-on-the-immune-gut-axis-in-obesity-100610738","NCT07231484","Effects of Grape Consumption on the Immune-Gut Axis in Obesity","Effects of Grape Consumption on Immune and Gut Health in the Setting of Obesity","Inclusion Criteria:\n\n* Age: 18-60 years\n* Obesity with BMI of 30-45 kg\u002Fm2\n* Willingness to consume study foods\n* Consistent diet and activity patterns for 4 weeks\n* Weight stable (\\\u003C5kg change over last 3 months)\n* Non-smoker \\> 1 year or more\n* Not currently consuming an extremely healthy diet\n\nExclusion Criteria:\n\n* Study food allergies\n* Regular consumption of grapes or grape-derived products\n* Gastrointestinal disease and\u002For bariatric surgery\n* Uncontrolled hypertension and blood pressure \\>180\u002F110\n* Diabetes\n* Illicit drug use\n* History of alcohol or drug abuse\n* Recent use of medications that affect immune function (e.g., corticosteroids)\n* Recent consumption of antibiotics, prebiotics, probiotics, symbiotics, or dietary supplements containing fiber or phytochemicals\n* Pregnant or lactating individuals\n* HIV positivity\n* Recent start of medications that affect metabolism or appetite\n* Drug therapy for coronary artery disease, peripheral artery disease, congestive","60 Years",{"count":109,"type":22},50,[25],"This study is investigating the benefits of whole freeze-dried grape powder consumption on the immune-gut axis in adults with obesity.",[113],"Obesity &Amp; Overweight",[115,116,117,118,119,120],"Obesity","Immunity","Microbiome","Gut","Grape","Stress","2026-07-30",{"date":123,"type":40},"2026-07-31",{"date":125,"type":40},"2025-12-19",{"date":127,"type":22},"2027-12-30",{"name":46,"class":47},{"id":130,"slug":131,"hasResults":12,"nctId":132,"briefTitle":133,"officialTitle":134,"acronym":4,"eligibilityCriteria":135,"healthyVolunteers":82,"sex":136,"minAge":137,"maxAge":138,"enrollmentInfo":139,"targetDuration":4,"studyType":23,"phases":141,"briefSummary":143,"conditions":144,"keywords":148,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":48},"100648853","phase-1-effects-of-sirolimus-on-asymptomatic-apoe4-carriers-100648853","NCT07728175","Effects of Sirolimus on Asymptomatic ApoE4 Carriers","Effects of Sirolimus on Middle Aged Asymptomatic ApoE4 Carriers","Inclusion Criteria:\n\n1. Willing and able to provide informed consent\n2. Sex assigned at birth: female\n3. 45-65 years old\n4. Able to perform self-care and activities of daily living with no or minimal assistance\n5. Post-menopausal status or use of highly effective contraception. Post-menopausal is defined as either\n\n   * 12 months of spontaneous amenorrhea with an appropriate clinical profile (e.g., age-appropriate, history of vasomotor symptoms)\n   * surgical bilateral oophorectomy (with or without hysterectomy), total hysterectomy, or tubal ligation at least 6 weeks prior to screening. For oophorectomy alone, post-menopausal status must be confirmed by follow-up hormone level assessment\n   * Highly effective contraception includes intrauterine devices (IUD), oral contraceptives, or other hormonal contraceptives including injectables, transdermal patches, implants or vaginal rings, or refraining from heterosexual intercourse during the 4 weeks of taking the study drug and for 2 weeks after no longer taking the study drug\n6. Body weight of ≥ 40 kg\n7. Ability to effectively communicate with the investigator and comply with study requirements\n\nExclusion Criteria:\n\n1. Diagnosis of mild cognitive impairment (MCI), dementia, or Alzheimer's disease\n2. BMI ≥ 35 (based on MRI feasibility)\n3. Type 1 diabetes or poorly controlled type 2 diabetes (HbA1c ≥ 6.5%)\n4. History of skin ulcers or poor wound healing\n5. Current tobacco or illicit drug use or alcohol abuse (defined as ≥ 3 per day or ≥ 7 per week for women) (Per NIAAA guidelines)\n6. Use of anti-platelet or anti-coagulant medications other than aspirin\n7. Required use of medications that affect cytochrome P450 3A4 (CYP3A4) or alter cerebral blood flow (see Appendix 1 for tables of excluded medications)\n8. Immunosuppressant therapy within the last year\n9. Chemotherapy or radiation treatment within the last year\n10. Current or chronic history of liver or kidney disease or known hepatic or biliary abnormalities\n11. Untreated hypertriglyceridemia (fasting triglycerides \\\u003C 300 mg\u002Fdl)\n12. Current or chronic significant history of pulmonary disease\n13. Chronic heart failure\n14. Pregnancy or lactation\n15. Recent history (past six months) of myocardial infarction, active coronary artery disease, intestinal disorders, stroke, or transient ischemic attack\n16. Poorly controlled blood pressure (systolic BP \\> 160 or diastolic BP \\> 100 mmHg)\n17. Active inflammatory, COVID-19, autoimmune, infectious, hepatic, gastrointestinal, malignant, and\u002For severe mental illness\n18. History of, or MRI, or CT positive for, any space occupying brain lesion, including mass effect or abnormal intracranial pressure\n19. Organ transplant recipients\n20. History of Stroke\n21. History of ruptured intracranial aneurysm\n22. History of malignancy within the past 2 years, with the following exceptions:\n\n    * Localized basal cell or squamous cell carcinoma of the skin\n    * Prostate cancer confined to the gland (AJCC stage T2N0M0 or better)\n    * Cervical carcinoma in situ\n    * Breast cancer localized to the breast\n23. History of epilepsy","FEMALE","45 Years","65 Years",{"count":140,"type":22},225,[142],"PHASE1","Alzheimer's disease is a devastating neurodegenerative disease characterized by accumulation of clumps (also called plaques) and bundles of fibers (also called tangles) in the brain, for which there is currently no cure.\n\nSirolimus (Rapamycin) is an FDA-approved medication which may improve the blood flow to the brain. The purpose of the clinical trial is to find out whether sirolimus can help improve blood flow and energy use in the brain in women ages 45 to 65 who have the ApoE4 gene, a gene which increases the risk of developing Alzheimer's disease later in life.\n\nThere will be two arms in this trail, a sirolimus arm and a placebo arm. A placebo is a pill that looks like the study drug, but it does not have any real medicine in it. Participants will be randomized to one arm or the other, but not to both arms. Three study visits over a 12-week period are required.\n\nParticipants will: (i) Complete some questionnaires about how well you think; (ii) Complete genetic testing for the ApoE4 gene; (iii) Have blood work, blood pressure and height and weight collected; (iv) Take either Sirolimus or a placebo daily, by mouth, for approximately 4 weeks; (v) Keep a diary of when the sirolimus or placebo is taken; (vi) Complete 2 Magnetic Resonance Imaging (MRI) exams",[145,146,147],"Genetic Predisposition to Disease","Healthy Volunteer","APOE-4 Positive",[149,150,151,152,153],"ApoE4 positive","Cerebral Blood Flow","Sirolimus","Rapamycin","Magnetic Resonance Imaging","2026-07-28",{"date":121,"type":40},{"date":157,"type":22},"2026-12-01",{"date":159,"type":22},"2028-07-07",{"name":46,"class":47},{"id":162,"slug":163,"hasResults":12,"nctId":164,"briefTitle":165,"officialTitle":166,"acronym":4,"eligibilityCriteria":167,"healthyVolunteers":12,"sex":17,"minAge":56,"maxAge":4,"enrollmentInfo":168,"targetDuration":4,"studyType":23,"phases":169,"briefSummary":170,"conditions":171,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":173,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":178,"locationsCount":48},"100635479","talar-osteochondral-lesions-with-pilon-fractures-100635479","NCT07553221","Talar Osteochondral Lesions With Pilon Fractures","Incidence and Management Implications of Talus Osteochondral Lesions in Tibial Plafond (Pilon) Fractures Identified Via Nano-Arthroscopy at Time of External Fixation: A Pilot Study","Inclusion Criteria:\n\n* Age ≥ 18 years (skeletally mature) Tibial plafond fractures with impaction of the articular surface requiring external fixation for temporization AO\u002FOrthopaedic Trauma Association (OTA) Fracture classification 43-C type fractures (excluding posterior pilon or supination-adduction type ankle fractures) Closed injury\n\nExclusion Criteria:\n\n* Prior ankle surgery\n\n  * Pre-existing ankle arthritis\n  * Unstable polytrauma patients precluding safe temporization\n  * Concomitant talus or calcaneus fractures identifiable on plain radiographs\n  * Pregnant\n  * Prisoner\n  * Unable to Consent",{"count":7,"type":22},[25],"Patients with pilon fractures have a high incidence of talar osteochondral lesions. In this study, patients will undergo ankle arthroscopy at the time of external fixation. The objective is to help determine the incidence of these lesions with pilon fractures and to see if these nano-arthroscopy results change the plan for definitive treatment.",[172],"Pilon Fractures",{"date":121,"type":40},{"date":175,"type":40},"2026-04-15",{"date":177,"type":22},"2031-04",{"name":46,"class":47},{"id":180,"slug":181,"hasResults":12,"nctId":182,"briefTitle":183,"officialTitle":184,"acronym":4,"eligibilityCriteria":185,"healthyVolunteers":12,"sex":17,"minAge":186,"maxAge":187,"enrollmentInfo":188,"targetDuration":4,"studyType":23,"phases":189,"briefSummary":190,"conditions":191,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":196,"completionDateStruct":198,"leadSponsor":200,"locationsCount":4},"100598131","impact-of-biphasic-cuirass-ventilation-compared-to-non-invasive-ventilation-in-high-risk-extubations-100598131","NCT07067502","Impact of Biphasic Cuirass Ventilation Compared to Non Invasive Ventilation in High Risk Extubations","Impact of Biphasic Cuirass Ventilation Compared to Non-Invasive Ventilation in High Risk Extubations","Inclusion Criteria:\n\n* High risk extubation patients in the Medical Intensive care units who are being thought to be placed on non invasive ventilator post extubation.\n\nExclusion Criteria:\n\n* Age \\\u003C18 or \\>80\n* Pregnant\n* Inmate\u002FPrisoner\n* Chest wall defects\n* BMI \\>50\n* History of Diaphragmatic paralysis\n* History of Neuromuscular disease\n* Contraindication to study device (open chest wound, flail chest, complex thoracic surgeries in the past)","19 Years","80 Years",{"count":109,"type":22},[25],"subjects on mechanical ventilator who are about to be extubated to Non invasive ventilation because the physician thinks they are high risk for failure will be approached and consented for our study. Once randomized they will either be on the standard of care Non invasive arm or the intervention arm which would mean they are placed on the Biphasic cuirass ventilation.",[192,193],"Respiratory Failure","Extubation Failure","2026-07-27",{"date":154,"type":40},{"date":197,"type":22},"2026-10-01",{"date":199,"type":22},"2027-07-30",{"name":46,"class":47},{"id":202,"slug":203,"hasResults":12,"nctId":204,"briefTitle":205,"officialTitle":205,"acronym":4,"eligibilityCriteria":206,"healthyVolunteers":82,"sex":136,"minAge":56,"maxAge":207,"enrollmentInfo":208,"targetDuration":4,"studyType":23,"phases":209,"briefSummary":211,"conditions":212,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":216,"lastUpdatePostDateStruct":217,"startDateStruct":218,"completionDateStruct":220,"leadSponsor":222,"locationsCount":48},"100644665","early-phase-1-beta3-adrenergic-receptors-and-cardiovascular-function-in-aging-women-100644665","NCT07674680","Beta3-adrenergic Receptors and Cardiovascular Function in Aging Women","Inclusion Criteria:\n\n* Healthy women,\n* Assigned female at birth,\n* 18-70 years of age,\n* Body mass index \\\u003C18 or ≥30 kg\u002Fm2,\n\nExclusion Criteria:\n\n* Assigned male at birth,\n* Pregnancy,\n* Breastfeeding,\n* History of hormone replacement therapy, chemical menopause, or oophor-ectomy\n* Polycystic ovarian syndrome or Primary ovarian insufficiency,\n* Current smoking\u002FNicotine use,\n* Blood pressure ≥140\u002F90 mmHg,\n* Increased risk of bleeding, pro-coagulant disorders, clotting disorders, anticoagulation therapy,\n* Nerve\u002Fneurologic disease,\n* Cardiovascular, hepatic, renal, respiratory disease,\n* Hypersensitivity to nitroglycerin,\n* Diabetes,\n* Communication barriers,","70 Years",{"count":5,"type":22},[210],"EARLY_PHASE1","To determine if vascular beta3 adrenergic receptors are present and functional in aging women and can be targeted to attenuate sympathetic vasoconstriction and enhance vascular function in aging women.",[213,214,215],"Women","Aging","Menopause","2026-07-24",{"date":154,"type":40},{"date":219,"type":22},"2026-07",{"date":221,"type":22},"2029-05",{"name":46,"class":47},{"id":224,"slug":225,"hasResults":12,"nctId":226,"briefTitle":227,"officialTitle":227,"acronym":4,"eligibilityCriteria":228,"healthyVolunteers":82,"sex":17,"minAge":56,"maxAge":138,"enrollmentInfo":229,"targetDuration":4,"studyType":23,"phases":231,"briefSummary":232,"conditions":233,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":216,"lastUpdatePostDateStruct":236,"startDateStruct":237,"completionDateStruct":239,"leadSponsor":241,"locationsCount":48},"100641635","early-phase-1-interplay-of-central-and-peripheral-vascular-effects-of-insulin-in-obesity-100641635","NCT07653464","Interplay of Central and Peripheral Vascular Effects of Insulin in Obesity","Inclusion Criteria:\n\n* 18 to 65 years of age\n\nIndividuals with obesity and comorbid IR\n\n* BMI 30-45 kg\u002Fm2\n* Waist circumference ≥102 cm (men) or ≥88 cm (women)\n* HOMA-IR ≥2.5\n\nHealthy normal weight adults\n\n* BMI 18-25 kg\u002Fm2\n* Waist circumference \\\u003C94 cm (men) and \\\u003C80 cm (women)\n* HOMA-IR \\\u003C2\n\nExclusion Criteria:\n\n* Pregnancy, breastfeeding\n* Unable to provide consent\n* Diabetes or polycystic ovarian syndrome\n* Known history of cardiovascular disease: heart failure, ischemic heart disease, peripheral artery disease, stroke\n* Nerve\u002Fneurologic disease\n* Uncontrolled hypertension (systolic blood pressure \\>180 mmHg and\u002For diastolic blood pressure \\>100 mmHg)\n* Active cancer (excluding basal cell carcinoma or stage 1 squamous cell carcinoma of the skin)\n* Current smoking, tobacco, nicotine use\n* Use of pharmacological therapy for weight loss\n* Body weight change \\>10% within the last 6 months\n* Adherence to \\>150 min\u002Fweek of moderate-to-vigorous physical activity\u002Fexercise\n* Participation in any other research study or medical procedure involving significant ionizing radiation exposure in the past 12 months\n* Claustrophobia\n* Non-MRI compatible metal implants",{"count":230,"type":22},64,[210],"Determine the impact of obesity with insulin resistance on the neurovascular response to brain insulin stimulation.",[234,235],"Obesity (BMI>30)","Insulin Resistance",{"date":154,"type":40},{"date":238,"type":22},"2026-10",{"date":240,"type":22},"2032-06",{"name":46,"class":47},{"id":243,"slug":244,"hasResults":12,"nctId":245,"briefTitle":246,"officialTitle":246,"acronym":4,"eligibilityCriteria":247,"healthyVolunteers":82,"sex":17,"minAge":56,"maxAge":137,"enrollmentInfo":248,"targetDuration":4,"studyType":23,"phases":250,"briefSummary":251,"conditions":252,"keywords":255,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":216,"lastUpdatePostDateStruct":257,"startDateStruct":258,"completionDateStruct":260,"leadSponsor":262,"locationsCount":48},"100630572","impact-of-sleep-restriction-on-blood-pressure-reactivity-100630572","NCT07489417","Impact of Sleep Restriction on Blood Pressure Reactivity","Inclusion Criteria:\n\n* Healthy adult men and women\n* 18-45 years of age\n* BMI \\\u003C 25 kg\u002Fm² (normal weight group) or ≥ 30 kg\u002Fm² (obesity group)\n* Non-pregnant, non-breastfeeding, and non-nicotine users\n* Self-reported history of normal sleep duration (7-9 hours\u002Fnight) and bedtime prior to midnight\n* Premenopausal\n\nExclusion Criteria:\n\n* No acute or chronic conditions\n* Taking no medications known to affect sleep, autonomic, metabolic, or cardiovascular function\n* Self-reported history of irregular sleep\n* Self-reported history of hepatic, renal, pulmonary, cardiovascular, or neurological disease, stroke or neurovascular disease, bleeding\u002Fclotting disorders, sleep apnea or other sleep disorders, diabetes, history of alcoholism or substance abuse, major cardiovascular event or surgical procedure within the past three months, or hypertension",{"count":249,"type":22},45,[25],"The purpose of the research study is to examine the effects of shortened sleep on blood pressure.",[253,254],"Sleep","Blood Pressure",[253,256],"Blood pressure",{"date":154,"type":40},{"date":259,"type":40},"2026-03-04",{"date":261,"type":22},"2027-08",{"name":46,"class":47},{"id":264,"slug":265,"hasResults":12,"nctId":266,"briefTitle":267,"officialTitle":267,"acronym":4,"eligibilityCriteria":268,"healthyVolunteers":82,"sex":17,"minAge":56,"maxAge":137,"enrollmentInfo":269,"targetDuration":4,"studyType":23,"phases":271,"briefSummary":272,"conditions":273,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":216,"lastUpdatePostDateStruct":275,"startDateStruct":276,"completionDateStruct":278,"leadSponsor":279,"locationsCount":48},"100456147","early-phase-1-sex-disparities-in-hypoxic-vasodilation-and-impact-of-obesity-100456147","NCT05219799","Sex Disparities in Hypoxic Vasodilation and Impact of Obesity","Inclusion Criteria:\n\n* BMI \\>18 kg\u002Fm2\n\nExclusion Criteria:\n\n* Pregnancy, breastfeeding\n* Diagnosed sleep apnea or AHI \\>10 events\u002Fhr\n* Current smoking\u002FNicotine use\n* Increased risk of bleeding, pro-coagulant disorders, clotting disorders, anticoagulation therapy\n* Nerve\u002Fneurologic disease\n* Cardiovascular, hepatic, renal, respiratory disease\n* Blood pressure ≥140\u002F90 mmHg\n* Diabetes, Polycystic ovarian syndrome\n* Communication barriers\n* Prescription medications, Sensitivity to lidocaine",{"count":270,"type":22},72,[210],"The purpose of this project is to examine key mechanisms contributing to sex-differences in hypoxic vasodilation and the impact of obesity, with particular emphasis on the sympathetic nervous system.",[115,274,89],"Vasodilation",{"date":154,"type":40},{"date":277,"type":40},"2023-03-14",{"date":199,"type":22},{"name":46,"class":47},{"id":281,"slug":282,"hasResults":12,"nctId":283,"briefTitle":284,"officialTitle":285,"acronym":4,"eligibilityCriteria":286,"healthyVolunteers":12,"sex":17,"minAge":287,"maxAge":288,"enrollmentInfo":289,"targetDuration":4,"studyType":23,"phases":291,"briefSummary":292,"conditions":293,"keywords":296,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":299,"lastUpdatePostDateStruct":300,"startDateStruct":302,"completionDateStruct":304,"leadSponsor":306,"locationsCount":48},"100609535","pars-healing-on-mri-100609535","NCT07215845","Pars Healing on MRI","Pars Healing on oZTEo MRI","Inclusion Criteria:\n\n* 12-30 years old\n* Symptoms of back pain at the time of enrollment\n* Clinical imaging demonstrating pars stress interarticularis injury or pars interarticularis defect\n\nExclusion Criteria:\n\n* Prior lumbar surgery\n* Any condition for which an MRI procedure is contraindicated (e.g., metallic material in the body such as pacemakers, metallic clips, etc.)\n* Pregnancy\n* Likelihood of claustrophobia\n* Any patient-related factors that compromised quality on the initial diagnostic scan (patient motion, ascites fluid, difficulty with positioning during the scan)","12 Years","30 Years",{"count":290,"type":22},40,[25],"The goal of this clinical trial is to learn more about the natural healing process of pars stress injuries in adolescents and young adults by documenting bony bridging across stress fractures using Magnetic Resonance Imaging (MRI). It is hypothesized that many of these injuries can and will heal with appropriate rest and rehabilitation. Long-term, it is hoped that follow-up MRI exams can help guide clinical management by visualizing the healing and allowing individuals to return to play after bony bridging has occurred.\n\nParticipants will be asked to undergo serial MRI scans over the course of a 12-month period and answer a brief questionnaire at each visit.",[294,295],"Pars Interarticularis Stress Fracture","Pars Interarticularis Stress Injury",[297,294,295,298],"MRI","Pars","2026-07-21",{"date":301,"type":40},"2026-07-22",{"date":303,"type":40},"2025-12-12",{"date":305,"type":22},"2028-12-31",{"name":46,"class":47},{"id":308,"slug":309,"hasResults":12,"nctId":310,"briefTitle":311,"officialTitle":312,"acronym":4,"eligibilityCriteria":313,"healthyVolunteers":12,"sex":17,"minAge":314,"maxAge":4,"enrollmentInfo":315,"targetDuration":4,"studyType":23,"phases":317,"briefSummary":318,"conditions":319,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":321,"lastUpdatePostDateStruct":322,"startDateStruct":324,"completionDateStruct":326,"leadSponsor":328,"locationsCount":48},"100521216","early-phase-1-propranolol-in-primary-progressive-aphasia-100521216","NCT06066710","Propranolol in Primary Progressive Aphasia","Trial of Propranolol in Older Adults With Primary Progressive Aphasia","Inclusion Criteria:\n\n* 1\\. Age: 50 and older\n* 2\\. Primary Progressive Aphasia diagnosis\n* 3\\. Native English speaker\n\nExclusion Criteria:\n\n* 1\\. Unable to provide consent\n* 2\\. Taking alpha 2 agonists (clonidine and guanfacine)\n* 3\\. Other major psychological or neurological diagnosis\n* 4\\. Major head trauma that contributed to their condition\n* 5\\. Allergic reaction to adhesives\n* 6\\. Uncorrected vision\u002Fhearing impairments\n* 7\\. Diabetes\n* 8\\. Reactive airway disease\n* 9\\. Untreated hypothyroidism\n* 10\\. Bradyarrhythmia\n* 11\\. Unexplained syncope\n* 12\\. Pregnancy (assessed verbally on the days of MR imaging)\n* 13\\. Drugs that interact with propranolol, such as alpha 2 agonists\n* 14\\. Claustrophobia, inner ear implants, aneurysm or other surgical clips, metal foreign bodies in eye, pacemaker or other contraindication to MR scanning. Subjects with any implanted device that cannot be verified as MRI compliant will be excluded.","50 Years",{"count":316,"type":22},30,[210],"The purpose of this study is to find out how the language of people with Primary Progressive Aphasia is affected by Propranolol. Propranolol is not FDA approved for the treatment of Primary Progressive Aphasia. Propranolol is FDA approved for the treatment of heart conditions such as blood pressure.\n\nThis research is being done because there are currently no drug treatment options for language impairments and anxiety often experienced by people with Primary Progressive Aphasia.",[320],"Aphasia, Primary Progressive","2026-07-15",{"date":323,"type":40},"2026-07-17",{"date":325,"type":40},"2025-01-13",{"date":327,"type":22},"2027-12",{"name":46,"class":47},{"id":330,"slug":331,"hasResults":12,"nctId":332,"briefTitle":333,"officialTitle":334,"acronym":335,"eligibilityCriteria":336,"healthyVolunteers":12,"sex":17,"minAge":337,"maxAge":338,"enrollmentInfo":339,"targetDuration":4,"studyType":86,"phases":4,"briefSummary":340,"conditions":341,"keywords":349,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":352,"lastUpdatePostDateStruct":353,"startDateStruct":355,"completionDateStruct":357,"leadSponsor":359,"locationsCount":48},"100546822","baker-gordon-syndrome-natural-history-study-100546822","NCT06399952","Baker Gordon Syndrome Natural History Study","A Prospective, Longitudinal and Observational Natural History Study for Children and Adults With Baker Gordon Syndrome - Genetic Autism Alliance","BAGOS","Inclusion Criteria:\n\n* Genetically confirmed diagnosis of Baker Gordon syndrome.\n* 0-99 years\n* Ability to send medical records and diagnostic test results.\n* Ability to complete tests and questionnaires.\n\nExclusion Criteria:\n\n• The presence of another condition or co-morbidity unrelated to Baker Gordon syndrome, that affects neurodevelopment.\n\nIn this study, the primary caregivers\u002FLAR for each participant diagnosed Baker Gordon Syndrome will be also considered participants.\n\nCaregivers\u002FLAR will have to meet the following inclusion criteria:\n\n* \\>18 years.\n* Legal caregiver of the patient diagnosed with a Baker Gordon Syndrome.\n* Willingness to follow study procedures, as assessed by the research team.\n* Willingness to sign the consent form.\n* Ability to understand all the information regarding the study, as assessed by the research team.\n\nCaregivers\u002FLAR Exclusion Criteria:\n\n• Less than 18 years old.","0 Years","99 Years",{"count":109,"type":22},"The goal of this study is to conduct a prospective, longitudinal assessment of the natural clinical progression of children and adults with Synaptotagmin1-Associated Neurodevelopmental Disorder also known as Baker Gordon Syndrome (BAGOS). This will be performed by acquiring baseline measurements and developing effective outcome measures and diagnostic tools for the disorder, to prepare the healthcare system for future clinical trials.",[342,343,344,345,346,347,348],"Rare Diseases","Autism or Autistic Traits","Development Delay","SYT-SSX Fusion Protein Expression","Sleep Disorder","Epilepsy, Generalized","Motor Delay",[350,335,351],"Baker Gordon Syndrome","Synaptotagmin 1-Associated Neurodevelopmental Disorder","2026-06-01",{"date":354,"type":40},"2026-06-03",{"date":356,"type":40},"2024-04-30",{"date":358,"type":22},"2027-05-05",{"name":46,"class":47},{"id":361,"slug":362,"hasResults":12,"nctId":363,"briefTitle":364,"officialTitle":365,"acronym":366,"eligibilityCriteria":367,"healthyVolunteers":12,"sex":17,"minAge":56,"maxAge":4,"enrollmentInfo":368,"targetDuration":4,"studyType":23,"phases":370,"briefSummary":372,"conditions":373,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":375,"lastUpdatePostDateStruct":376,"startDateStruct":377,"completionDateStruct":379,"leadSponsor":381,"locationsCount":48},"100376551","phase-4-subjective-intraoperative-use-of-epidural-steroid-administration-following-discectomy-100376551","NCT04182997","Subjective Intraoperative Use of Epidural Steroid Administration Following Discectomy","Subjective Intraoperative Use of Epidural Steroid Administration Following Discectomy for Herniated Lumbar Discs Is There a Role? - A Randomized Control Trial","Intra-Op","Inclusion Criteria:\n\n* Presenting to the University of Missouri hospital system - including the University of Missouri Hospital and Missouri Orthopaedic Institute - with a clinical assessment indicative of a lumbar disc herniation\n* Failed conservative treatment - rest, anti-inflammatory medications, physical therapy\n* Radiculopathy present - positive tension signs or sensory\u002Fmotor neurologic deficits present\n* Recent MRI confirming single-level lumbar disc herniation corresponding to clinical evaluation\n\nExclusion Criteria:\n\n* Concomitant spinal stenosis, segmental instability, or spondylolisthesis\n* Previous surgery at the affected level or recurrent herniation\n* Underlying disease that may affect response to steroids - immunocompromise, use of chronic steroids or immunosuppression\n* Pregnancy - qualitative human chorionic gonadotropin (hCG) testing will be performed prior to enrollment\n* Diagnosis of or symptoms concerning for cauda equina syndrome",{"count":369,"type":22},200,[371],"PHASE4","The purpose of this study is to determine a grading system for inflammation in lumbar disc herniation and which groups, if any, benefit most from the administration of an intra-operative epidural steroid.",[374],"Lumbar Disc Herniation","2026-05-31",{"date":354,"type":40},{"date":378,"type":40},"2019-11-21",{"date":380,"type":22},"2026-12",{"name":46,"class":47},{"id":383,"slug":384,"hasResults":12,"nctId":385,"briefTitle":386,"officialTitle":386,"acronym":387,"eligibilityCriteria":388,"healthyVolunteers":82,"sex":17,"minAge":56,"maxAge":83,"enrollmentInfo":389,"targetDuration":4,"studyType":86,"phases":4,"briefSummary":390,"conditions":391,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":392,"lastUpdatePostDateStruct":393,"startDateStruct":395,"completionDateStruct":397,"leadSponsor":398,"locationsCount":48},"100560004","growth-hormone-resistance-of-beta-cells-in-people-with-a-family-history-of-type-2-diabetes-100560004","NCT06571500","Growth Hormone Resistance of Beta-cells in People With a Family History of Type 2 Diabetes","GHRB-B","Inclusion Criteria:\n\n* 18 to 59 years old\n* body mass index ≥30.0 kg\u002Fm2 and \\\u003C45.0 kg\u002Fm2\n\nAdditional, group-specific inclusion criteria:\n\n* Family history of type 2 diabetes: first degree relative with type 2 diabetes\n* Control group: no family history of type 2 diabetes\n\nExclusion Criteria:\n\n* Pregnant, planning to become pregnant during the study, or breastfeeding\n* Current diagnosis or history of type 1 or type 2 diabetes\n* Use of medications that can impact the study outcomes (e.g., GLP-1 receptor agonists)\n* History of bariatric surgery\n* Known, uncontrolled hypothyroidism\n* History of intracranial hypertension, including papilledema, or a condition that increases the risk of developing intracranial hypertension, such as Turner Syndrome, Prader-Willi Syndrome, or renal impairment\n* Current cancer or cancer that has been in remission less than 5 years\n* First degree relative with type 1 diabetes diagnosis\n* Evidence of significant anemia or significant end organ dysfunction (e.g., liver, kidney, heart disease)\n* Alcohol use disorder, use of controlled substances, or smoking \\>2 cigarettes per day\n* Greater than 3% weight loss within three months of screening or engaged in regular (≥3 days per week), continuous moderate- or high-intensity exercise of ≥30 min duration\n* Mentally disabled persons, prisoners, and persons with inability to grant voluntary informed consent",{"count":316,"type":22},"The purpose of the research study is to better understand how beta-cells (cells in the pancreas that make insulin and help regulate blood sugar) respond to growth hormone in people with a family history of type 2 diabetes at the University of Missouri. Our aim is to advance understanding of how growth hormone affects beta-cells and risk factors for developing type 2 diabetes.",[89,115],"2026-05-05",{"date":394,"type":40},"2026-05-11",{"date":396,"type":40},"2025-07-15",{"date":98,"type":22},{"name":46,"class":47},{"id":400,"slug":401,"hasResults":12,"nctId":402,"briefTitle":403,"officialTitle":404,"acronym":405,"eligibilityCriteria":406,"healthyVolunteers":82,"sex":136,"minAge":56,"maxAge":137,"enrollmentInfo":407,"targetDuration":4,"studyType":86,"phases":4,"briefSummary":408,"conditions":409,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":392,"lastUpdatePostDateStruct":411,"startDateStruct":412,"completionDateStruct":414,"leadSponsor":415,"locationsCount":48},"100560003","growth-hormone-resistance-of-beta-cells-a-100560003","NCT06571487","Growth Hormone Resistance of Beta-cells A","Growth Hormone Resistance of Beta-cells in Women With Gestational Diabetes Mellitus","GHRB-A","Inclusion Criteria:\n\n* Singleton, full term pregnancy within the past 5 years\n* Body mass index ≥18.5 kg\u002Fm2 and \\\u003C45.0 kg\u002Fm2\n\nGroup specific inclusion criteria:\n\n* Gestational Diabetes Group: History of gestational diabetes in the most recent pregnancy\n* Control Group: no history of gestational diabetes\n\nExclusion Criteria:\n\n* Pregnant, planning to become pregnant during the study, or breastfeeding\n* Current diagnosis or history of type 1 or type 2 diabetes\n* Use of medications that can impact the study outcomes (e.g., GLP-1 receptor agonists)\n* History of bariatric surgery\n* Known, uncontrolled hypothyroidism\n* History of intracranial hypertension, including papilledema, or a condition that increases the risk of developing intracranial hypertension, such as Turner Syndrome, Prader-Willi Syndrome, or renal impairment\n* Current cancer or cancer that has been in remission less than 5 years\n* First degree relative with diabetes diagnosis\n* Evidence of significant anemia or significant end organ dysfunction (e.g., liver, kidney, heart disease)\n* Alcohol use disorder, use of controlled substances, or smoking \\>2 cigarettes per day\n* Greater than 3% weight loss within three months of screening or engaged in regular (≥3 days per week), continuous moderate- or high-intensity exercise of ≥30 min duration\n* Mentally disabled persons, prisoners, and persons with inability to grant voluntary informed consent",{"count":316,"type":22},"The purpose of the research study is to better understand how beta-cells (cells in the pancreas that make insulin and help regulate blood sugar) respond to growth hormone in people with a personal history of gestational diabetes (high blood sugar in pregnancy) at the University of Missouri. The aim of the study is to advance understanding of how growth hormone affects beta-cells and risk factors for developing gestational diabetes.",[410,115,89],"Gestational Diabetes",{"date":394,"type":40},{"date":413,"type":40},"2025-10-22",{"date":98,"type":22},{"name":46,"class":47},{"id":417,"slug":418,"hasResults":12,"nctId":419,"briefTitle":420,"officialTitle":421,"acronym":422,"eligibilityCriteria":423,"healthyVolunteers":82,"sex":17,"minAge":137,"maxAge":424,"enrollmentInfo":425,"targetDuration":4,"studyType":23,"phases":426,"briefSummary":427,"conditions":428,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":392,"lastUpdatePostDateStruct":430,"startDateStruct":431,"completionDateStruct":433,"leadSponsor":435,"locationsCount":48},"100457351","high-protein-diet-and-atherosclerosis-100457351","NCT05235464","High Protein Diet and Atherosclerosis","Dissecting the Impact of Dietary Protein on Macrophage mTOR Signaling and Atherosclerosis","HPA","Inclusion Criteria:\n\n* \\>=45 and \\\u003C=75 years of age\n* body mass index \\>=25.0 and \\\u003C40.0 kg\u002Fm2\n\nExclusion Criteria:\n\n* \\\u003C45 and \\>75 years of age\n* body mass index \\\u003C25.0 or \\>39.9 kg\u002Fm2\n* plasma triglyceride \\\u003C125 mg\u002Fdl\n* history of or current significant organ system dysfunction\n* allergies or intolerances to meal ingredients\n* use of medications or dietary supplements that could confound the study outcomes\n* engaged in regular structured exercise \\>150 min per week\n* alcohol use disorder\n* premenopausal women\n* persons who smoke\n* prisoners\n* inability to grant voluntary informed consent","75 Years",{"count":21,"type":22},[25],"Atherosclerosis is the underlying cause of the majority of cardiovascular diseases, including myocardial infarction and strokes, and results in tremendous morbidity and mortality. A Western-type diet is a major risk factor for atherosclerosis because of the high saturated fat, cholesterol, and refined carbohydrate contents. Dietary strategies to reduce cardiovascular disease burden therefore focus on restriction of saturated fat, cholesterol, and refined carbohydrates whereas \"lean\" protein intake is recommended and has become popular. However, results from studies conducted in animal models suggest high dietary protein intake is also atherogenic. The investigators' extensive preliminary data in animal models show that dietary protein increases atherosclerotic plaque formation and size and promotes necrotic core formation, a characteristic of rupture-prone plaques. The goal of the current proposal is to provide deeper insights into the relationship between protein intake and the pathogenesis of atherosclerosis by studying the mechanisms involved in protein-mediated atherogenesis and formation of necrotic plaques. The overarching hypothesis is that high protein intake drives atherosclerosis via leucine-mediated mTORC1 signaling in macrophages, which inhibits macrophage mitophagy and aggrephagy and stimulates macrophage proliferation. Furthermore, the investigators hypothesize that proteins from animal sources are more atherogenic than proteins from plant sources, because animal proteins contain more leucine than plant proteins. The investigators will test these hypotheses by using a sophisticated array of experimental strategies, including assays in primary macrophages and human monocyte-derived macrophages and genetically engineered mouse models. In addition, they will begin to translate the results obtained in vitro and in animals to people, and explore approaches to pharmacologically target the pro-atherogenic pathways as novel cardiovascular therapeutics. This proposal represents a paradigm shift in how a Western-type diet affects vascular health which has important implications since many adults in Western societies consume excess protein and dietary protein is heavily marketed for its presumed beneficial health effects.",[429],"Atherosclerosis",{"date":394,"type":40},{"date":432,"type":40},"2023-03-13",{"date":434,"type":22},"2028-03-31",{"name":46,"class":47},{"id":437,"slug":438,"hasResults":12,"nctId":439,"briefTitle":440,"officialTitle":440,"acronym":441,"eligibilityCriteria":442,"healthyVolunteers":82,"sex":17,"minAge":443,"maxAge":207,"enrollmentInfo":444,"targetDuration":4,"studyType":23,"phases":445,"briefSummary":446,"conditions":447,"keywords":451,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":392,"lastUpdatePostDateStruct":455,"startDateStruct":457,"completionDateStruct":459,"leadSponsor":461,"locationsCount":48},"100362068","animal-and-plant-proteins-and-glucose-metabolism-100362068","NCT03994367","Animal and Plant Proteins and Glucose Metabolism","HP","Inclusion Criteria:\n\n* age: ≥21 and ≤70 years;\n* BMI: \\>24.5 and \\\u003C32.5 kg\u002Fm2;\n* habitual protein intake \\\u003C0.9 g\u002Fkg\u002Fday (assessed on 2 weekdays and 2 weekend days by using the HealthWatch 360 app); and\n* weight stable (i.e., ≤3% change) and untrained (≤150 min of structured exercise\u002Fweek) for at least 2 months before entering the study.\n\nExclusion Criteria:\n\n* prediabetes or type 2 diabetes;\n* evidence of chronic kidney disease by medical history or laboratory tests (glomerular filtration rate \\\u003C60 ml\u002Fmin\u002F1.73 m2 or an albumin to creatinine ratio in urine ≥30 mg\u002Fg);\n* vegetarians or vegans;\n* intolerance or allergies to ingredients in the metabolic meal or intervention diet;\n* take dietary supplements (e.g., pre- and probiotics, fiber, fish oil) or medications known to affect our study outcomes;\n* received antibiotic or antifungal treatment (which affect the microbiome and therefore microbial metabolite production) 2 months before entering the study;\n* consume tobacco products or excessive alcohol (women: \\>14 drinks\u002Fweek; men: \\>21 drinks\u002Fweek);\n* evidence of significant organ system dysfunction or diseases (e.g., cirrhosis), and\n* unwilling or unable to provide informed consent.","21 Years",{"count":58,"type":22},[25],"The goal of this proposal is to determine the effect of a high protein diet in which the increase in protein intake is derived from different sources (animal vs plant and protein-rich whole foods vs protein isolates) on: i) liver and muscle insulin sensitivity; ii) the metabolic response to a meal, and iii) 24-h plasma concentration profiles of glucose, glucoregulatory hormones, and protein-derived metabolites purported to cause metabolic dysfunction.",[448,449,450],"Metabolic Syndrome","Metabolic Syndrome, Protection Against","Glucose Metabolism Disorders",[452,453,454],"High Protein","Metabolism","Diet",{"date":456,"type":40},"2026-05-08",{"date":458,"type":40},"2019-07-12",{"date":460,"type":22},"2028-04-25",{"name":46,"class":47},{"id":463,"slug":464,"hasResults":12,"nctId":465,"briefTitle":466,"officialTitle":466,"acronym":4,"eligibilityCriteria":467,"healthyVolunteers":82,"sex":136,"minAge":56,"maxAge":468,"enrollmentInfo":469,"targetDuration":4,"studyType":23,"phases":470,"briefSummary":471,"conditions":472,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":475,"lastUpdatePostDateStruct":476,"startDateStruct":477,"completionDateStruct":479,"leadSponsor":481,"locationsCount":48},"100504294","effect-of-drain-care-on-infection-rate-and-quality-of-life-in-implant-based-breast-reconstruction-100504294","NCT05846438","Effect of Drain Care on Infection Rate and Quality of Life in Implant-Based Breast Reconstruction.","Inclusion Criteria:\n\n* undergoing breast surgery with placement of tissue expander and drains, acceptance of protocol and procedures, age \\> 18\n\nExclusion Criteria:\n\n* no existing wounds, previous infections related to implant device if delayed, refusal by patient","100 Years",{"count":58,"type":22},[25],"The goal of this clinical trial is to learn whether showering with surgical drain tubes in place after first stage breast reconstruction causes increased risk of infection. The main questions it aims to answer are:\n\n* Is there an increased risk of infection\u002Fcomplications with showering 48 hours after drain tubes are in place\n* Does showering after 48 hours with drain tubes in place affect quality of life.",[473,474],"Infections","Quality of Life","2026-04-28",{"date":392,"type":40},{"date":478,"type":40},"2023-03-15",{"date":480,"type":22},"2028-03-15",{"name":46,"class":47},{"id":483,"slug":484,"hasResults":12,"nctId":485,"briefTitle":486,"officialTitle":487,"acronym":4,"eligibilityCriteria":488,"healthyVolunteers":12,"sex":17,"minAge":56,"maxAge":107,"enrollmentInfo":489,"targetDuration":4,"studyType":23,"phases":491,"briefSummary":492,"conditions":493,"keywords":497,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":504,"lastUpdatePostDateStruct":505,"startDateStruct":507,"completionDateStruct":509,"leadSponsor":511,"locationsCount":48},"100622552","evaluation-of-cognitive-behavioral-therapy-for-insomnia-cbt-i-in-individuals-with-mild-traumatic-brain-injury-mtbi-100622552","NCT07385105","Evaluation of Cognitive Behavioral Therapy for Insomnia (CBT-I) in Individuals With Mild Traumatic Brain Injury (mTBI)","Exploring Cognitive Behavioral Therapy for Insomnia (CBT-I) in Mild Traumatic Brain Injury (mTBI)","Inclusion Criteria:\n\n* A history of mTBI documented by a physician and sleep problems for more than 4 weeks\n* A score ≥ 10 on the Insomnia Severity Index (ISI)\n* Speak, read, and write English\n\nExclusion Criteria:\n\n* History of other neurological or psychological conditions\n* Patient Health Questionnaire-9 (PHQ-9) score higher than 20 (severe depressive symptoms)\n* Generalized Anxiety Disorder-7 (GAD-7) score higher than 15 (severe anxiety symptoms)\n* Montreal Cognitive Assessment (MoCA) score less than 24",{"count":490,"type":22},15,[25],"This study will employ cognitive behavioral therapy for insomnia (CBT-I) among individuals with mild traumatic brain injury (mTBI) who experience sleep disturbances. The research aims to evaluate the effects of CBT-I on sleep, mTBI symptoms, and, in particular, the ability of individuals with mTBI to engage in their desired daily life activities. The main questions this study aims to answer are:\n\n1. Does CBT-I positively impact symptoms of mTBI?\n2. Does CBT-I improve functional performance in individuals with mTBI?",[494,495,253,496],"Sleep Architecture","Mild Traumatic Brain Injury","Sleep and Circadian Problems",[498,499,500,501,502,503],"Sleep problems","Cognitive behavioral Therapy for insomnia","CBT-I","mild traumatic brain injury","mTBI","Functional performance","2026-04-27",{"date":506,"type":40},"2026-05-01",{"date":508,"type":40},"2026-03-01",{"date":510,"type":22},"2027-01-01",{"name":46,"class":47},{"id":513,"slug":514,"hasResults":12,"nctId":515,"briefTitle":516,"officialTitle":517,"acronym":4,"eligibilityCriteria":518,"healthyVolunteers":82,"sex":17,"minAge":56,"maxAge":314,"enrollmentInfo":519,"targetDuration":4,"studyType":23,"phases":521,"briefSummary":522,"conditions":523,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":504,"lastUpdatePostDateStruct":525,"startDateStruct":526,"completionDateStruct":527,"leadSponsor":529,"locationsCount":4},"100618589","insomnia-and-insulin-resistance-100618589","NCT07333586","Insomnia and Insulin Resistance","Insomnia, Metabolic Syndrome and Insulin Resistance","Inclusion Criteria:\n\nages 18-50 y BMI 28-45 kg\u002Fm2 Score on the Insomnia Severity Index ≥15.\n\nExclusion Criteria:\n\ncontraindications for CBT-I (mania or seizure disorder) symptoms requiring immediate attention (e.g., psychosis, suicide intent) report illicit substance use on a monthly basis (e.g., cocaine, opioids) receiving behavioral treatment for insomnia overt cardiovascular disease overt renal disease thyroid disease cancer pregnant dieting using GLP-1 agonists taking exogenous insulin",{"count":520,"type":22},20,[25],"Insomnia symptoms are linked to metabolic syndrome (MetS), which includes abnormal glucose metabolism, insulin resistance (IR), and incidence of diabetes. Chronic sleep deficit is a major predictor of disease and early mortality. Further, insomnia is the most common sleep disorder in the United States. The recommended first line of treatment for insomnia is Cognitive Behavioral Therapy for Insomnia (CBT-I). CBT-I is a multidimensional treatment that targets the thoughts and behaviors that perpetuate insomnia symptoms over time. This study will explore CBT-I effects on MetS outcomes (ie. blood pressure, triglycerides, etc.) and provide preliminary evidence that CBT-I impacts IR and fasting glucose concentrations within this population.\n\n20 subjects with insomnia will be recruited. They will be randomly assigned to either CBT-i or sleep hygiene. The intervention is 5 wks. Pre and post intervention, the investigator will have participants fill out a number of questionnaires, a daily sleep diary, 2 weeks of actigraphy measuring sleep and physical activity and there will be a single blood draw at the beginning and the end of the study.",[524,235],"Insomnia",{"date":475,"type":40},{"date":352,"type":22},{"date":528,"type":22},"2027-06-01",{"name":46,"class":47},{"id":531,"slug":532,"hasResults":12,"nctId":533,"briefTitle":534,"officialTitle":535,"acronym":4,"eligibilityCriteria":536,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":443,"enrollmentInfo":537,"targetDuration":4,"studyType":23,"phases":538,"briefSummary":539,"conditions":540,"keywords":542,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":504,"lastUpdatePostDateStruct":545,"startDateStruct":546,"completionDateStruct":548,"leadSponsor":550,"locationsCount":48},"100609562","the-feasibility-of-a-remote-problem-solving-intervention-for-autistic-adolescents-or-young-adults-and-a-caregiver-100609562","NCT07216196","The Feasibility of a Remote Problem-Solving Intervention for Autistic Adolescents or Young Adults and a Caregiver","The Effect of Dyadic Metacognitive Strategy Training in Autistic Youth or Young Adults and a Primary Caregiver","Inclusion Criteria:\n\n* Autistic adolescents aged 13-21 AND one primary parent, guardian, or caregiver aged 18 or older\n* At least one year remaining in high school\n* Ability to engage in reciprocal conversation\n* Ability to provide informed consent\u002Fassent as part of an adapted procedure designed to prevent coercion and protect the rights of autistic adolescents with or without intellectual disability\n\nExclusion Criteria:\n\n* Severe or profound intellectual disability (IQ\\\u003C35)\n* Severe mental health conditions that interfere with ability to participate in the intervention\n* Currently enrolled in community-based transition services redundant with remote PREP",{"count":21,"type":22},[25],"This project seeks to evaluate the feasibility and acceptability of a remote metacognitive strategy training intervention in transition-age autistic adolescents and young adults and a primary caregiver. We will also conduct limited efficacy testing.",[541],"Autism",[31,541,543,544],"Transition to Adulthood","Waitlist Crossover",{"date":475,"type":40},{"date":547,"type":40},"2026-04-08",{"date":549,"type":22},"2027-05-03",{"name":46,"class":47},{"id":552,"slug":553,"hasResults":12,"nctId":554,"briefTitle":555,"officialTitle":555,"acronym":4,"eligibilityCriteria":556,"healthyVolunteers":82,"sex":17,"minAge":56,"maxAge":4,"enrollmentInfo":557,"targetDuration":4,"studyType":86,"phases":4,"briefSummary":559,"conditions":560,"keywords":567,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":504,"lastUpdatePostDateStruct":572,"startDateStruct":573,"completionDateStruct":575,"leadSponsor":577,"locationsCount":48},"100273409","tumor-cell-and-dna-detection-in-the-blood-urine-and-bone-marrow-of-patients-with-solid-cancers-100273409","NCT02838836","Tumor Cell and DNA Detection in the Blood, Urine and Bone Marrow of Patients With Solid Cancers","Inclusion Criteria:\n\n* Subjects older than 18 years.\n* Subjects of all genders and ethnicities.\n* Subjects with the diagnosis of a solid cancer (n=100) of all stages will be included (lung, esophageal, stomach, bile duct\u002Fpancreas, colorectal, melanoma, sarcoma).\n* Ten patients with no present suspicion and no previous history of any cancer (except basal cell cancer of the skin) that undergo surgeries for other benign indications will serve as controls (n=20).\n* In patients undergoing surgery for cancer the histopathology should preferably be pathologically proven by a previous or novel biopsy. Yet, patients with a high cancer suspicion by radiology and clinical picture that undergo cancer surgery will not be excluded. No additional biopsies, testing or interventions will be performed for the purpose of this study if the medical treatment will not require it.\n* Subjects must be capable of giving informed consent.\n\nExclusion Criteria:\n\n* Pregnant women.\n* Subjects with the concurrent diagnosis of an active secondary (synchronous) malignancy besides basal cell carcinoma of the skin will be excluded, if there is evidence of disease burden or if the patient is currently being treated with chemotherapy.\n* Subjects with a hemoglobin of \\\u003C8g\u002Fdl in the morning of the procedure will be excluded.\n* In subjects who require intraoperative transfusions of \\>4 units of red packed blood cells (RPBCs), no further blood will be drawn for CTC\u002FDTC\u002FcfDNA analysis during surgery or on postoperative day 1.\n* In patients with coagulation disorders that could lead to significant bleeding (such as hemophilia, significant thrombocytopenia) requiring prophylactic administration of coagulative products, no bone marrow aspiration will be performed.",{"count":558,"type":22},620,"Patients with resectable solid primary cancers and even limited number of metastases are potentially curable. However, most patients develop recurrences despite surgery. Circulating and disseminated tumor cell (CTC\u002FDTC) and circulating cell-free (cf) DNA isolation from the blood, urine and bone marrow will increase understanding of cancer spread and advance knowledge to develop individualized therapies.",[561,562,563,564,565,566],"Non-small Cell Lung Cancer","Esophageal Cancer","Gastric Cancer","Pancreatic Cancer","Hepatocellular Cancer","Colorectal Cancer",[568,569,570,571],"Cancer","Circulating tumor cells (CTCs)","Disseminated tumor cells (DTCs)","Circulating tumor DNA (ctDNA)",{"date":506,"type":40},{"date":574,"type":40},"2016-07-01",{"date":576,"type":22},"2027-12-01",{"name":46,"class":47},{"id":579,"slug":580,"hasResults":12,"nctId":581,"briefTitle":582,"officialTitle":582,"acronym":4,"eligibilityCriteria":583,"healthyVolunteers":12,"sex":17,"minAge":56,"maxAge":4,"enrollmentInfo":584,"targetDuration":4,"studyType":23,"phases":585,"briefSummary":586,"conditions":587,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":590,"lastUpdatePostDateStruct":591,"startDateStruct":592,"completionDateStruct":594,"leadSponsor":595,"locationsCount":48},"100470089","phase-4-skin-preparation-for-elective-foot-and-ankle-surgery-100470089","NCT05401292","Skin Preparation for Elective Foot and Ankle Surgery","Inclusion Criteria:\n\n* patients undergoing elective foot and ankle surgeries\n* age over 18\n\nExclusion Criteria:\n\n* trauma as the indication for surgery\n* open injuries\n* non-elective procedures\n* amputations\n* prior surgical site infection through the planned incision\n* pregnancy. All potential participants of child-bearing potential follow the standard pre-operative protocol to ensure they are not in pregnant status prior to SOC surgical procedure.",{"count":58,"type":22},[371],"Surgical site infections (SSIs) make about 31% of all nosocomial infections and they are the most common hospital-acquired infection. For foot and ankle elective interventions, SSI rate is reported between 0.4% and 3.6%. This study will investigate the effectiveness of skin cleaning with isopropyl alcohol and scrubbing with chlorhexidine soap before standard skin preparation in reducing microbial load and surgical site infections for elective foot and ankle surgeries. Current standard of care includes skin preparation with iodine or chlorhexidine solution prior to sterile draping and the start of surgery. Standard of care will be applied to all patients. The use of an additional \"pre-scrub\" with isopropyl alcohol and scrubbing with chlorhexidine soap will be applied to the experimental group. The control group will receive only the standard of care skin preparation with iodine or chlorhexidine solution prior to draping.",[588,589],"Microbial Colonization","Foot and Ankle Disorders","2026-04-23",{"date":504,"type":40},{"date":593,"type":40},"2022-02-15",{"date":380,"type":22},{"name":46,"class":47},""]